LIGAND PHARMACEUTICALS INCORPORATED Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
LIGAND PHARMACEUTICALS INCORPORATED (LGND) had Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss of $37.00 thousand as of 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Notes › Credit Losses › ASU 2016-13 Transition
us-gaap:HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss · last filed 2023-02-28
- 2022-12-31: Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss $37.00K.
- 2021-12-31: Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss $60.00K.
- 2020-12-31: Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss $0.00.
- 2019-12-31: Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss $0.00.
| Period end | Debt Securities, Held-to-maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss |
|---|---|
| 2022-12-31 | $37.00K 10-K · filed 2023-02-28 |
| 2021-12-31 | $60.00K 10-K · filed 2023-02-28 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-28 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-24 |